APOE and early-onset autosomal dominant Alzheimer disease: The potential use of APOE data to risk stratify persons with AVM is further supported by well-designed studies aimed at evaluating the feasibility and consequences of returning genetic information to patients.22,23,24 Those studies found that disclosing the APOE ε4 status, which is also a well-established risk factor for Alzheimer disease, led to improvements in beneficial health habits without significant short-term psychological adverse effects.22 In addition, direct-to-consumer companies have made this information available to millions of Americans in recent years.